Skip to main content

10 Result(s)

within Kiran Naqvi Remove this filter

and

  1. Article

    Open Access

    A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis

    In TP53 wild-type acute myeloid leukemia (AML), inhibition of MDM2 can enhance p53 protein expression and potentiate leukemic cell apoptosis. MDM2 inhibitor (MDM2i) monotherapy in AML has shown modest responses i...

    Jayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, Hussein A. Abbas… in Blood Cancer Journal (2023)

    Download PDF (1772 KB) View Article

  2. Article

    Open Access

    Decreasing delirium through music listening (DDM) in critically ill, mechanically ventilated older adults in the intensive care unit: a two-arm, parallel-group, randomized clinical trial

    Delirium is a highly prevalent and morbid syndrome in mechanically ventilated intensive care unit (ICU) patients. Music is a promising non-pharmacological intervention with beneficial effects on anxiety and st...

    Sarah Seyffert, Salwa Moiz, Matthew Coghlan, Patil Balozian, Jason Nasser… in Trials (2022)

    Download PDF (1608 KB) View Article

  3. No Access

    Article

    Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

    Guillermo Montalban-Bravo, Danielle Hammond, Courtney D. DiNardo… in Leukemia (2021)

  4. No Access

    Article

    Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

    CPX-351 is a liposomal formulation of cytarabine/daunorubicin with a 5:1 fixed molar ratio. We investigated the safety and efficacy of escalating doses of CPX-351 in patients with acute myeloid leukemia (AML) ...

    Ghayas C. Issa, Hagop M. Kantarjian, Lianchun **ao, **g Ning, Yesid Alvarado… in Leukemia (2020)

  5. No Access

    Article

    A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

    Prithviraj Bose, Srdan Verstovsek, Jorge E. Cortes, Susan Tse, Yvonne Gasior… in Leukemia (2020)

  6. No Access

    Article

    Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes

    Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and cytopenias due to uncontrolled programmed cell death. The presence of pro-inflammatory cytokines and constitutive activation o...

    Guillermo Montalban-Bravo, Caleb A. Class, Irene Ganan-Gomez… in Leukemia (2020)

  7. No Access

    Reference Work Entry In depth

    What the Intensivist Needs to Know About Leukemia Patients

    Acute leukemias are devastating diseases. Advancements in antileukemic therapy and early recognition and management of complications have led to improved survival. Some of the life-threatening complications as...

    Mahesh Swaminathan, Kiran Naqvi in Oncologic Critical Care (2020)

  8. No Access

    Living Reference Work Entry In depth

    What the Intensivist Needs to Know About Leukemia Patients

    Acute leukemias are devastating diseases. Advancements in antileukemic therapy and early recognition and management of complications have led to improved survival. Some of the life-threatening complications as...

    Mahesh Swaminathan, Kiran Naqvi in Oncologic Critical Care

  9. No Access

    Article

    Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR–ABL kinase domain mutations

    Kinase domain (KD) mutations of ABL1 represent the most common resistance mechanism to tyrosine kinase inhibitors (TKI) in CML. Besides T315I, mutations in codon 255 are highly resistant mutations in vitro to ...

    Kiran Naqvi, Jorge E. Cortes, Raja Luthra… in International Journal of Hematology (2018)

  10. No Access

    Article

    An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL)

    Mixed phenotype acute leukemia (MPAL) is an uncommon diagnosis, representing only about 2–5% of acute leukemia cases. The blast cells of MPAL express multilineage immunophenotypic markers and may have a shared...

    Maliha Khan, Rabbia Siddiqi, Kiran Naqvi in Annals of Hematology (2018)